MedTrace Logo

Neurobiology of Opioid Dependence: 2 - 2

NCT00000193 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-08-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.

Conditions

  • Opioid-Related Disorders

Interventions

DRUG

Gamma hydroxybutyric

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Marc I Rosen, M.D. · VA Connecticut Healthcare System

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-01-31
Primary Completion
1998-01-31
Completion
1998-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000193 on ClinicalTrials.gov